Earlier this morning, REGENXBIO released financial and operating results for the third quarter ended September 30, 2025.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback